MedTrace Logo

Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer

NCT05652348 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2025-05-29

No results posted yet for this study

Summary

Patients with gastric or colon cancer with peritoneal carcinomatosis will receive a biopsy of the tumor during their primary curative surgery. The operation is performed according to standard and includes resection of the primary tumor and any metastases and followed by HIPEC (Intraperitoneal hyperthermic chemoperfusion) according to the respective hospital standard. Organoid cultures from the biopsies are established in the research laboratory.

Various chemotherapeutic agents are tested on these tumor organoids in the laboratory and the tumor organoids are analyzed in detail with regard to genetic alterations in order to find alterations that can be addressed, if necessary, by means of targeted drugs against peritoneal carcinomatosis.

Conditions

Interventions

OTHER

Establishment of organoid cultures and in vitro sensitivity testing

Generating patient-derived tumor organoid models as well as orthotopic mouse models from peritoneal carcinomatosis lesions and to investigate their response to different therapies.

Sponsors & Collaborators

  • German Cancer Research Center

    collaborator OTHER

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Daniel Stange, Prof. Dr. · University Hospital Carl Gustav Carus Dresden

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-08
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05652348 on ClinicalTrials.gov